Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

0.9830 +0.0891 (+9.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,606,526
Open 0.8850
Bid (Size) 0.9660 (300)
Ask (Size) 0.9750 (1,000)
Prev. Close 0.8939
Today's Range 0.8744 - 1.000
52wk Range 0.6400 - 7.290
Shares Outstanding 54,291,754
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers in Thursday's session ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill

Performance

YTD
+29.5%
+29.5%
1 Month
+39.1%
+39.1%
3 Month
+44.5%
+44.5%
6 Month
-80.0%
-80.0%
1 Year
-74.1%
-74.1%

More News

Read More
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Bragar Eagel & Squire, P.C. Urgently Reminds Stockholders of Molina, aTyr, and Marex to Contact the Firm Before Upcoming Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Urges Investors of aTyr, Marex, Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Investors Who Lost Money on aTyr Pharma, Inc. (ATYR) Should Contact Levi & Korsinsky About Pending Class Action - ATYR
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on aTyr Pharma, Inc. (ATYR) Should Contact Levi & Korsinsky About Pending Class Action - ATYR
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
aTyr Pharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
aTyr Pharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
aTyr Pharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
aTyr Pharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is aTyr Pharma, Inc. - Common Stock publicly traded?
Yes, aTyr Pharma, Inc. - Common Stock is publicly traded.
What exchange does aTyr Pharma, Inc. - Common Stock trade on?
aTyr Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for aTyr Pharma, Inc. - Common Stock?
The ticker symbol for aTyr Pharma, Inc. - Common Stock is ATYR on the Nasdaq Stock Market
What is the current price of aTyr Pharma, Inc. - Common Stock?
The current price of aTyr Pharma, Inc. - Common Stock is 0.9830
When was aTyr Pharma, Inc. - Common Stock last traded?
The last trade of aTyr Pharma, Inc. - Common Stock was at 02/17/26 04:00 PM ET
What is the market capitalization of aTyr Pharma, Inc. - Common Stock?
The market capitalization of aTyr Pharma, Inc. - Common Stock is 53.37M
How many shares of aTyr Pharma, Inc. - Common Stock are outstanding?
aTyr Pharma, Inc. - Common Stock has 53M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.